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In continuation of the study of antibody in lobar pneumonia 342 
mouse protection tests have been done on 63  patientst  as follows: 
17 Type I, 4 Type II and 5 Type III pnettmococcus infections which 
had no specific therapy and 29 Type I  and 8 Type II cases treated 
with Felton's antibody.  The method has already been described (1). 
Our findings in the series are, on the whole, similar to those obtained 
by Neufeld  and  Haendel (2), Dochez (3),  Clough (4), Baldwin and 
Rhoades (5) and Trask, O'Donovan, Moore and Beebe (6) and serve to 
amplify and sustain the results presented in a previous communication 
dealing with a part of this material (1). 
In view of substantial agreement as to the usual results of mouse 
protection tests in pneumonia, it seems unnecessary to present our 
findings in detail, but certain aspects of the relation of antibody to 
pneumonia  deserve further brief discussion. 
Early Appearance of Antibody and Its Relation to the Time of Recovery 
In general in our series, as noted by Dochez (3) in his investigation, 
the time of appearance of antibody coincides rather sharply with the 
* This investigation was made with assistance from  the Proctor Fund of Har- 
vard University, the Committee on Therapeutic Research, Council on Pharmacy 
and Chemistry of the American Medical Association and the American Associa- 
tion for the Advancement of Science. 
t  The material from 31 of these cases was kindly furnished by Drs. W. D. Sut- 
lift and Maxwell Finland of the  Boston City Hospital and from 9  cases by Drs. 
George Walker and Samuel Shelburne from the service of Dr. Henry A. Christian 
at the Peter Bent Brigham Hospital.  We are indebted to Dr. Lloyd D.  Felton 
for virulent cultures of the pneumococcus. 
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period of critical fall in the temperature.  Our opportunity to investi- 
gate the early period of the disease has been limited.  The serum from 
eight patients tested during the 1st or 2nd day showed no protective 
power.  Protection was demonstrated as early as the 3rd day in three 
(one Type I, one Type II and one Type III) of eleven cases, and on the 
4th day in five (four Type I and one Type III) of fourteen cases. 
As shown in the accompanying chart (Chart 1) in one patient (Case 
1,  Type I)  with protection on  the 3rd day,  the  temperature  fell to 
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~T  1. Early appearance of antibody and'its relation to time of recovery. 
O  =  no mouse survivals.  +  =  one or more surviving mice.  \  --- fall in 
temperature.  AA  =  irregular temperature  fall.  The figures in the upper space 
show the number  of thousands  of Felton units of the corresponding type which 
were administered after the serum sample was taken. 
normal on the 4th day and in another (Case 5, Type I) with protection 
on the 4th day the patient became afebrile the same day.  The early 
appearance of protection is not, however, always followed by a  speedy 
termination of the disease, as the two other patients (Case 1, Type II, 
and Case 1, Type III) with protection on the 3rd day remained febrRe 
until the 6th while three (Case 3, Type I, Case 2, Type I, and  Case 4 
Type I) with protection on the 4th day had fever until the 7th, 9th and 
10th  day respectively,  in  spite of considerable  amounts  of Felton's 
antibody after the collection of the first blood sample. ]~ILEDERICK T. LORD  AND  ELBERT  L. PERSONS  153 
Recovery without Demonstrable Antibody 
Recovery without demonstrable protection during or immediately 
after the fall in temperature was noted in two of ten cases by Dochez 
(3).  One of these (Experiment 9) showed protective substance 16 days 
after crisis,  on  the 22nd  day of  the disease.  Clough  (4)  failed  to 
demonstrate protective power after crisis or lysis in three of twelve 
cases, but in these three only one specimen of serum was tested.  One 
(Case 9) of Baldwin and Rhoades' cases (5)  had a crisis on the 15th 
day without protective substance in the serum, but later developed a 
fatal bacteriemia.  Two of our seventeen untreated Type I  cases had 
no demonstrable antibody at or near the time of crisis.  In one of these, 
with crisis on the 8th day, the blood was negative when tested on the 
8th, 9th, 10th, 12th, 14th and 20th days and was not tested thereafter. 
In the other, with crisis on  the 6th day, the blood was negative  on 
the 4th, 5th, 6th, 8th, 1  lth and 17th days but showed protection on the 
25th, 32nd and 39th days after onset.  A  third  Type I  case, which 
received 60,000  units of Felton's Type I antibody near the time of his 
crisis on  the 3rd day, showed no protection on the 3rd day (before 
serum), the irregular survival of only one of fourteen mice on the 5th 
day, and no protection on the 6th, 8th or llth days, but by the 29th day 
after onset showed a  relatively high degree of protection.  The late 
appearance of protection in the last two cases is an assurance that the 
disease was due to a  Type I  infection.  These three cases illustrate 
the importance of frequent repetition of tests to avoid erroneous nega- 
tive results. 
The significance of the absence of protective substance at the time 
of recovery and its appearance later is not clear.  It is possible that 
mouse protection tests measure only an excess of antibody  over the 
amount needed for recovery.  It is also possible, in view of Goodner's 
(8) and TiUett's (9) inability to protect mice with immune rabbit serum 
that mouse tests as an index of available antibody are not wholly r~eli- 
able and that a part of the human antibodies are undemonstrable with 
an alien species.  Another explanation involves the presence in  the 
blood  serum of an  antagonistic substance,  sufficient in  amount  to 
inhibit mouse protection during the course of the infection and its 
disappearance after recovery. 154  MOUSE  PROTECTION  TESTS  IN  PNEIT~fONIA 
Irregular Protection  Tests in Mice 
Irregular  protection tests are not uncommon in  the investigations 
of others.  Of a total of ~29" mouse protection tests, 75 show scattered 
or irregular  survivals of mice, and in 33 tests these irregularities  are 
marked  enough  to make it impossible to  estimate  the  approximate 
number of lethal  doses of pneumococci against wluch the individual 
serum sample protected.  We are unable to trace these sporadic sur- 
vivals to any error in technic, and it seems probable that the survival 
of even one mouse, in the absence of technical error and in view of the 
death of the control mice, indicates the presence of some protective 
substance in the serum injected with the organisms. 
Amount of Antibody in Untreated Cases 
As noted by Dochez (3) the amount of protection demonstrable at 
the time of crisis, though variable, is small compared with the potency 
of sera obtained  by  active  immunization  of larger  animals.  Of 17 
untreated cases in our series, tested within 1 day on either side of crisis, 
12 (8 Type I, 1 Type II, 3 Type III) had protective power against 100 
lethal doses or less of pneumococci of corresponding type and none of 
the remaining five (3 Type I, 2 Type II) had protective power against 
more than 10,000 lethal doses.t 
Amount of Protection in Treated Cases 
In  attempting  to  estimate  the  effect of late  intravenous  specific 
treatment on the protective power of the patient's serum, the problem 
is complicated by the usual production during the course of the disease 
of small and varying amounts of protective substances by the infected 
individual himself. 
Twenty-nine surviving  cases,  treated with Felton's  antibody, had 
protection tests on 1 of the 3 days centering at the critical fall in tem- 
perature.  Of  these,  eleven  (all  Type  I)  showed  protective  power 
* This figure includes a miscellaneous group of 37 protection tests which has not 
been included in the series, consisting of cases on which only one test was done, 
cases in which a reliable history was lacking, Type IV cases which were tested 
against types for which antibody had been administered and the like. 
t The equivalent of only 0.05 Felton units per cubic centimeter of serum. ~'P.EDERICK  T.  LORD  .AND ELBERT  L.  PERSONS  155 
against every dose of culture used, up to and including one million 
lethal doses.  Of five fatal treated cases, three (2 Type I, 1 Type II) 
showed the same protective power within 1 day of death.  Thus, in 
14 out of 34 treated cases it was possible to demonstrate more protec- 
tive substance in the serum than would have been expected in un- 
treated cases at the time the tests were made. 
The Bearing of Protection Tests on Dosage 
In attempting to estimate appropriate dosage by mouse protection 
tests account must be taken of the usual spontaneous production of 
small amounts of antibody during  the  course of the disease.  The 
problem is complicated by occasional recovery  without evidence of any 
protective substance and the lack of any definite correlation between 
the amount of protection and the time of recovery or the apparent 
severity  of the disease. 
It would be valuable to know the approximate dosage necessary to 
produce a large protective balance in the blood stream.  In nineteen 
instances (18  Type I,  1 Type II)  where protection tests* followed 
specific intravenous therapy with less  than 200,000 Felton units be- 
tween the 3rd and 6th days there was protection in amounts not other- 
wise to be expected in only  six (all Type I).  Of eight cases (7 Type I, 
1 Type II) treated between the2nd and the 7th dayswith over 200,000 
units only one (Type I) failed to show unusual protective power:  In 
general it may be said that doses of less than 200,000 Felton units are 
likely to be inadequate for the production of an unusual amount of pro- 
tection in the blood stream.  It must be added, however, that we have 
found protection against a million lethal doses in the serum after doses 
as small as 25,000 Felton units and yet this amount of protection has 
failed to appear after as much as 400,000 units. 
The Presence of Antibody with Septicemia 
In Baldwin and Rhoades (5) experience, bacteriemia and protective 
substances occurred simultaneously  in the blood in only one instance in 
a total of 45 specimens of blood.  We have been able to demonstrate 
protective substances late in the disease in blood from which pneumo- 
cocci were cultivated in three instances. 
* These tests were  done  on blood taken not less than 8 hours after treatment. 156  MOUSE  PROTECTION  TESTS  IN  PNEUMONIA 
One of our cases came to the hospital because of empyema following  pneumonia 
and did not improve after surgical drainage.  On the 83rd day of his disease the 
blood culture was positive for Type I  pneumococcus in spite of the presence of 
mouse protection  against 100,000 lethal doses.  No specific treatment  had been 
given.  Autopsy 3 days later showed a Type I pneumococcus endocarditis. 
The second case was observed throughout his disease* and was given no specific 
treatment.  The blood was sterile on the 2nd day but from the 8th until death on 
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CHART 2.  The presence of antibody with septicemia. 
A severe case, showing the effect of treatment with antibody on the blood cul- 
ture and protective substances early in the disease.  After the antibody was dis- 
continued the patient developed septicemia in spite of  protective power in the blood. 
The "normal" base line drops from 99.6 ° to 98.6°F. on the 12th day when mouth 
temperatures were substituted for rectal readings,  o----o  -  amount of protec- 
tion.  X  =  irregular mouse survivals.  B.C.  -- blood culture. 
the 23rd day showed Type I pneumococci in each of nine cultures.  No protective 
substance was demonstrated from the 10th to the 13th day by three tests, but on 
the 17th and 21st days, when blood culture showed a few organisms, his serum 
protected against  1,000 and  1,000,000  lethal doses respectively, and on the day 
of death there were numerous irregular mouse survivals.  Thoracentesis on the 
11th and 12th days produced  infected fluid in small amounts but none was obtain- 
* At the Boston City Hospital. FREDERICK  T.  LORD  AND  ELBERT  L.  PEI~SONS  157 
able on the 18th day and there were no other signs of localization of the infection. 
Autopsy was refused. 
In a third case (Chart 2), also Type I, there were extensive areas of consolidation 
involving all but the right middle  lobe.  In spite of early and intensive  treatment a 
right-sided empyema developed.  Respiratory exchange was  maintained by the 
use  of an oxygen tent and he did well until the 18th day when he had a chill and 
showed a positive Type I blood culture with protection in the blood serum against 
10,000 lethal doses 13 days after his last treatment with antibody.  There  were no 
signs of extension of the lung involvement, but a rough systolic murmur and a 
pericardial friction rub persisted until death.  No autopsy was granted. 
These first two cases demonstrate that the formation of some pro- 
tective  substances  by  the  patient  himself is  no  assurance  against 
further progress  of the infection to  a  fatal termination.  Although 
in the third case intensive specific therapy was used, the lapse of 13 
days between the last dose of antibody and the time the final serum 
sample was taken makes it questionable whether the protective sub- 
stances were due to the treatment or not. 
CONCLUSIONS 
1.  Though in general in pneumococcus pneumonia the appearance 
of protective substance coincides rather sharply with the fall in the 
temperature, antibody may appear spontaneously in the blood serum 
as early as the 3rd or 4th day and crisis and recovery may be delayed 
until the 6th to the 10th day. 
2.  Recovery at times occurs without demonstrable protective sub- 
stance in the blood in patients who later develop protection. 
3.  The amount of antibody developed in the course of pneumococcus 
pneumonia is small and in the majority of cases tested was insufficient 
to protect against more than 100 lethal doses of homologous pneumo- 
cocci and never against more than 10,000 lethal doses. 
4.  Treatment  with  Felton's  antibody late  in  the  course  of  the 
disease materially increases  the amount of protective substances in 
the blood.  A high degree of protection may be established by treat- 
ment in fatal cases.  After the 3rd  day doses of more than 200,000 
Felton units are usually necessary to produce a greater degree of pro- 
tection than might otherwise be expected. 
5.  The formation of protective substances by the patient himself is 
not an assurance against progress of the infection to a fatal termination. 158  ~OUSE  PROTECTION  TESTS  IN PNEUMONIA 
6.  Protective substance in the blood and pneumococcic septicemia 
may occur simultaneously. 
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